Short-Term and Long-Term Outcome of Anti-Jo1-Positive Patients with Anti-Ro52 Antibody

Marie, I.; Hatron, P.Y.; Dominique, S.; Chérìn, P.; Mouthon, Luc; Ménard, Jean-François; Lévesque, H.; Jouen, F.

doi:10.1016/j.semarthrit.2011.09.008

Cited by 196 publications

(139 citation statements)

References 35 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…Here, we report 3 cases of ILD associated with positivity for ANA with weak titer and for anti-SS-A/Ro autoantibody, satisfying the proposed criteria for lung-dominant CTD [3], which responded very well to immunosuppressive treatment. Our observation, if confirmed in larger cohorts of patients, suggests a possible favorable course, in spite of an aggressive onset, differently from anti-synthetase syndrome in which the concomitant positivity for anti-SS-A/Ro was associated with a great severity [6,7]. Two patients showed a clinical response to a traditional approach represented by an initial therapy with MMF mycophenolate mofetil, RTX rituximab corticosteroid and cyclophosphamide followed by MMF; a third patient required a more aggressive treatment with addition of two cycles of rituximab.…”

Section: Discussionsupporting

confidence: 62%

“…The isolated positivity for anti-SS-A/Ro52 antibody may also be found in patients affected by myositis, frequently together with anti-Jo1 antibody, SSc and autoimmune liver diseases [4,5]. In addition, anti-SS-A/Ro antibody has been detected in apparently idiopathic ILD [1] and its presence is a marker of ILD severity in patients affected by anti-synthetase syndrome [6,7]. In the current literature, there are few data on treatment and outcome of lung-dominant CTD associated with SS-A/Ro antibody positivity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dramatic improvement of anti-SS-A/Ro-associated interstitial lung disease after immunosuppressive treatment

et al. 2016

View full text Add to dashboard Cite

The aim of the study was to report three patients affected by interstitial lung disease associated with positive anti-SS-A/Ro autoantibody who showed a dramatic improvement after immunosuppressive treatment. Medical charts were reviewed to obtain clinical data, laboratory parameters, lung function tests, high-resolution computed tomography results and response to immunosuppressive treatment. The three patients showed a clinical picture of a lung-dominant connective tissue disease characterized by a sudden onset with dyspnea, cough and subtle extrathoracic features together with positive anti-SS-A/Ro antibody and weak titer antinuclear antibodies. All three patients responded favorably to immunosuppressive therapy: Two cases were treated with a combination of corticosteroid and cyclophosphamide followed by mycophenolate mofetil; in the third patient, clinical benefit was obtained after rituximab was added to corticosteroid and immunosuppressant drug. In spite of an abrupt onset with significant lung function impairment, all three patients had a favorable clinical response to immunosuppressive therapy. This report may be useful in making therapeutic decisions in case of interstitial lung disease associated with anti-SS-A antibody.

show abstract

Section: Discussionsupporting

confidence: 62%

Section: Introductionmentioning

confidence: 99%

Dramatic improvement of anti-SS-A/Ro-associated interstitial lung disease after immunosuppressive treatment

et al. 2016

View full text Add to dashboard Cite

show abstract

“…For a similar reason, follow-up PFT could not be performed in most of the patients with severe dyspnea. Third, myositis-specific antibodies (MSAs) except anti-Jo1, which are associated with the outcome of DM, were not fully evaluated [27][28][29].…”

Section: Discussionmentioning

confidence: 99%

Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease

Park

Kang

et al. 2015

Rheumatol Int

View full text Add to dashboard Cite

Interstitial lung disease (ILD) is the most common cause of death in dermatomyositis (DM). Cyclosporine A (CsA) has shown to be effective in DM-associated ILD (DM-ILD). This study aimed to define the optimal time of CsA administration. A total of 47 patients with DM-ILD, who were treated with CsA at Seoul National University Hospital between January 1998 and June 2013, were enrolled. ILD was diagnosed based on typical chest high-resolution computed tomography (HRCT) findings. Patients with early and delayed CsA treatment were compared in regard to the mortality and ILD progression on HRCT. The early (n = 16) and the delayed treatment group (n = 31) did not differ in regard to baseline clinical characteristics including HRCT scores and pulmonary function. Patients with clinically amyopathic DM (CADM) were more common in the early treatment group. The mortality rate was significantly lower in the early treatment group than in the delayed treatment group (p = 0.009). The survival benefit of early CsA treatment remained significant even after adjusting for age, degree of dyspnea, CADM status, and the year of CsA treatment (hazard ratio 0.057, 95 % confidence interval 0.007-0.472). CsA stabilized disease progression on HRCT in the early treatment group (p = 0.738). Delay in CsA treatment is associated with a worse survival in patients with DM-ILD. Early CsA treatment should be considered at DM-ILD diagnosis especially in patients at a higher risk of developing a rapidly progressive ILD.

show abstract

“…Reportedly, phenotypes (e.g., myositis) may be altered in patients with concurrent anti-SSA antibodies, hallmarks of Sjögren syndrome. 13 These alterations include perivascular inflammation, 15 myositis deterioration, malignant disease, 32 left ventricular diastolic dysfunction, 33 interstitial lung disease 34 and death. 32 Sjögren syndrome combined with other autoimmune diseases was associated with increased T-cell activation, 35 Raynaud phenomenon, 36 thyroid disease, 37 cardiac electrical instability 38 and lymphoma, 39 more so than with the respective autoimmune diseases alone.…”

Section: Discussionmentioning

confidence: 99%

Sex differential association of dermatomyositis with Sjögren syndrome

Tseng

Chang

Tsai

et al. 2017

CMAJ

View full text Add to dashboard Cite

Short-Term and Long-Term Outcome of Anti-Jo1-Positive Patients with Anti-Ro52 Antibody

Cited by 196 publications

References 35 publications

Dramatic improvement of anti-SS-A/Ro-associated interstitial lung disease after immunosuppressive treatment

Dramatic improvement of anti-SS-A/Ro-associated interstitial lung disease after immunosuppressive treatment

Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease

Sex differential association of dermatomyositis with Sjögren syndrome

Contact Info

Product

Resources

About